| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2126163 | European Journal of Cancer | 2006 | 8 Pages |
Abstract
In conclusion, 1 in every 10 children treated with a cumulative anthracycline dose of 300Â mg/m2 or more will eventually develop A-CHF. This is an extremely high risk and it reinforces the need of re-evaluating the cumulative anthracycline dose used in different treatment protocols and to define strategies to prevent A-CHF which could be implemented in treatment protocols.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Elvira C. van Dalen, Helena J.H. van der Pal, Wouter E.M. Kok, Huib N. Caron, Leontien C.M. Kremer,